[1]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
|
[2]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:The major impact of China[J].Hepatology,2014,60(6):2099-2108.
|
[3]HENDRIKX T,SCHNABL B.Antimicrobial proteins:Intestinal guards to protect against liver disease[J].J Gastroenterol,2019,54(3):209-217.
|
[4]SENDER R,FUCHS S,MILO R.Revised estimates for the number of human and bacteria cells in the body[J].PLo S Biol,2016,14(8):e1002533.
|
[5]HARTMANN P,CHEN WC,SCHNABL B.The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease[J].Front Physiol,2012,3:402.
|
[6]LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
|
[7]BHAT M,ARENDT BM,BHAT V,et al.Implication of the intestinal microbiome in complications of cirrhosis[J].World J Hepatol,2016,8(27):1128-1136.
|
[8]GINS P,QUINTERO E,ARROYO V,et al.Compensated cirrhosis:Natural history and prognostic factors[J].Hepatology,1987,7(1):122-128.
|
[9]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118studies[J].J Hepatol,2006,44(1):217-231.
|
[10]van ERPECUM KJ.Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Scand J Gastroenterol Suppl,2006,243:79-84.
|
[11]GINS P,CRDENAS A,ARROYO V,et al.Management of cirrhosis and ascites[J].N Engl J Med,2004,350(16):1646-1654.
|
[12]BENTEN D,WIEST R.Gut microbiome and intestinal barrier failure-the“Achilles heel”in hepatology?[J].J Hepatol,2012,56(6):1221-1223.
|
[13]WIEST R,KRAG A,GERBES A.Spontaneous bacterial peritonitis:Recent guidelines and beyond[J].Gut,2012,61(2):297-310.
|
[14]WIEST R,GARCIA-TSAO G.Bacterial translocation(BT)in cirrhosis[J].Hepatology,2005,41(3):422-433.
|
[15]NOLAN JP.The role of intestinal endotoxin in liver injury:A long and evolving history[J].Hepatology,2010,52(5):1829-1835.
|
[16]GILL SR,POP M,DEBOY RT,et al.Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
|
[17]CHEN Y,YANG F,LU H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology,2011,54(2):562-572.
|
[18]SANTIAGO A,POZUELO M,POCA M,et al.Alteration of the serum microbiome composition in cirrhotic patients with ascites[J].Sci Rep,2016,6:25001.
|
[19]KANG Y,CAI Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
|
[20] QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
|
[21]LU H,WU Z,XU W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
|
[22]TUOMISTO S,PESSI T,COLLIN P,et al.Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics[J].BMC Gastroenterol,2014,14:40.
|
[23]BAJAJ JS,BETRAPALLY NS,HYLEMON PB,et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology,2015,62(4):1260-1271.
|
[24]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.
|
[25]WEI X,YAN X,ZOU D,et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterol,2013,13:175.
|
[26]FAITH JJ,GURUGE JL,CHARBONNEAU M,et al.The longterm stability of the human gut microbiota[J].Science,2013,341(6141):1237439.
|
[27]BAJAJ JS,HEUMAN DM,HYLEMON PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
|
[28]BALMER ML,SLACK E,de GOTTARDI A,et al.The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota[J].Sci Transl Med,2014,6(237):237ra66.
|
[29]PONZIANI FR,ZOCCO MA,CERRITO L,et al.Bacterial translocation in patients with liver cirrhosis:Physiology,clinical consequences,and practical implications[J].Expert Rev Gastroenterol Hepatol,2018,12(7):641-656.
|
[30]TANG R,WEI Y,LI Y,et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut,2018,67(3):534-541.
|
[31]YANG R,XU Y,DAI Z,et al.The immunologic role of gut microbiota in patients with chronic HBV infection[J].J Immunol Res,2018,2018:2361963.
|
[32]TILG H,CANI PD,MAYER EA.Gut microbiome and liver diseases[J].Gut,2016,65(12):2035-2044.
|
1. | 张玉婷,施欢,李虤,沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 . ![]() | |
2. | 杜乔慧,吴克俭,王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 . ![]() | |
3. | 鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 . ![]() | |
4. | 毛桂芸,张永飞,郭延生,陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 . ![]() | |
5. | 陈晓玲,宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 . ![]() | |
6. | 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . ![]() | |
7. | 张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 . ![]() | |
8. | 尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 . ![]() | |
9. | 黄春明,胡中伟,聂玉强,周永健,詹远京,郭家伟,余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 . ![]() | |
10. | 黄春明,杨湛,聂玉强,胡中伟,周永健,詹远京,郭家伟,余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . ![]() | |
11. | 李曼,李涛,刘振杰,曹永坚,钟伟国,余婷玉,何敏,徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 . ![]() | |
12. | 李曼,张军,李涛,罗强,钟伟国,李嘉胜,徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 . ![]() |